These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7933531)

  • 1. Evaluation of minocycline and cefuzonam for antimicrobial activity against clinical isolates.
    Igari J; Oguri T; Higuchi T
    Jpn J Antibiot; 1994 Aug; 47(8):1013-29. PubMed ID: 7933531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bacteriological evaluations of combination therapies with minocycline and beta-lactams for methicillin-resistant Staphylococcus aureus. II. cefuzonam plus minocycline].
    Deguchi K; Yokota N; Koguchi M; Nakane Y; Suzuki Y; Fukayama S; Ishihara R
    Jpn J Antibiot; 1992 Jun; 45(6):605-11. PubMed ID: 1507394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antimicrobial activities of cefuroxime against recent clinical isolates].
    Deguchi K; Yokota N; Koguchi M; Suzuki Y; Fukayama S; Ishihara R; Oda S; Tanaka S; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1994 Apr; 47(4):365-82. PubMed ID: 8201767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Susceptibilities of clinical bacterial isolates to antimicrobial agents. A study mainly focused on imipenem. Reported by the Research Group for Testing Imipenem Susceptibility on Clinical Isolates].
    Igari J
    Jpn J Antibiot; 1990 Nov; 43(11):1956-2002. PubMed ID: 2287060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination chemotherapy for infections due to methicillin-resistant Staphylococcus aureus with combination therapy by cefuzonam and fosfomycin or minocycline in the urologic field.
    Matsumoto T; Kubo S; Haraoka M; Takahashi K; Tanaka M; Sakumoto M; Kumazawa J
    Clin Ther; 1993; 15(5):819-28. PubMed ID: 8269448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative antibacterial activity of cefpodoxime against Haemophilus influenzae, Streptococcus pyogenes, Streptococcus pneumoniae and Moraxella catarrhalis].
    Wallrauch-Schwarz C; Milatovic D; Braveny I
    Arzneimittelforschung; 1994 May; 44(5):668-70. PubMed ID: 8024645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
    Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
    Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1996)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Shimizu Y; Terai T; Inoue H; Nakadate T; Ito C; Yoshida T; Ohno I; Tanno Y; Arakawa M; Igarashi K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Nakata K; Nakatani T; Inagawa H; Kusano N
    Jpn J Antibiot; 1998 Jul; 51(7):437-74. PubMed ID: 9755430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Susceptibilities of clinical bacterial isolates to antimicrobial agents. A study mainly focused on imipenem. Research Group for Testing Imipenem Susceptibility on Clinical Isolates].
    Igari J
    Jpn J Antibiot; 1990 Oct; 43(10):1723-82. PubMed ID: 2086814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1993)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Feb; 49(2):107-43. PubMed ID: 8721076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antimicrobial activity of cefodizime against clinical isolates].
    Suzuki Y; Ishihara R; Ishii Y; Nakazawa A; Deguchi K; Matsumoto Y; Nishinari C; Nakane Y; Fukumoto T
    Jpn J Antibiot; 1996 Oct; 49(10):947-65. PubMed ID: 8986558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibacterial activity of cefpodoxime against clinical isolates in 2000 and 2001].
    Abe T; Fukuoka T; Sato Y; Ito K; Sei M
    Jpn J Antibiot; 2002 Dec; 55(6):827-43. PubMed ID: 12621736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1993). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H
    Jpn J Antibiot; 1995 Nov; 48(11):1757-87. PubMed ID: 8558757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical laboratory approach for estimating effective administrative dose of cefuzonam. Evaluation of disc susceptibility test and its interpretation system].
    Uete T; Matsuo K
    Jpn J Antibiot; 1988 Oct; 41(10):1407-17. PubMed ID: 3204654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
    Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT
    Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2004)].
    Goto H; Takeda H; Kawai S; Watanabe T; Okazaki M; Shimada K; Nakano K; Yokouchi H; Ikemoto H; Mori T; Igari J; Oguri T; Yamamoto M; Inoue H; Nakadate T; Suwabe A; Ashino Y; Gejyo F; Okada M; Aoki N; Kitamura N; Suzuki Y; Karasawa Y; Kudo K; Kobayashi N; Tanaka T; Sumitomo M; Matsushima T; Oka M; Niki Y; Suga M; Tosaka M; Kohno S; Hirakata Y; Kondou A; Matsuda J; Nakano M; Nasu M; Hiramatsu K; Oikawa S
    Jpn J Antibiot; 2006 Oct; 59(5):323-54. PubMed ID: 17180803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro evaluation of cefpodoxime.
    Valentini S; Coratza G; Rossolini GM; Massidda O; Satta G
    J Antimicrob Chemother; 1994 Mar; 33(3):495-508. PubMed ID: 8040114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.